Rosacea: an update on therapeutic options
Abstract
Keywords
Full Text:
PDFReferences
Webster GF. Rosacea. Med Clin North Am. 2009;93:1183-94.
Gooderham M. Rosacea and its topical management. Skin Therapy Lett. 2009;14:1-3.
Baldwin HE. Diagnosis and treatment of rosacea: state of the art. J Drugs Dermatol. 2012;11:725-30.
Yamasaki K, Gallo RL. The molecular pathology of rosacea. J Dermatol Sci. 2009;55:77-81.
Wilkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odom R, et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46:584-7.
Aksoy B, Altaykan-Hapa A, Egemen D, Karagöz F, Atakan N. The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities. Br J Dermatol. 2010;163:719-25.
Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol. 2003;48:836-45.
Thiboutot DM, Fleischer AB Jr, Del Rosso JQ, Graupe K. Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. J Drugs Dermatol. 2008;7:541-6.
Gupta AK, Grover MD. Azelaic acid (15% gel) in the treatment of acne rosacea. Int J Dermatol. 2007;46:533-8.
Pye RJ, Burton JL. Treatment of rosacea by metronidazole. Lancet. 1976;1:1211-2.
Yoo Y, Reid DC, Kimball AB. Metronidazole in the treatment of rosacea: do formulation, dosing, and concentration matter? J Drugs Dermatol. 2006;5:317-9.
Nielsen PG. A double-blind study of 1% metronidazole cream versus systemic oxytretracycline therapy for rosacea. Br J Dermatol. 1983;109:63-5.
Maddin A. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol. 1999;40:961-5.
Elewski BE, Fleischer AB, Jr., Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol. 2003;139:1444-50.
Goldman D. Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report. J Am Acad Dermatol. 2001;44:995-8.
Woo DK, James WD. Topical tacrolimus: a review of its uses in dermatology. Dermatitis. 2005;16:6-21.
Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol. 2004;51:499-512.
Garg G, Thami GP. Clinical efficacy of tacrolimus in rosacea. J Eur Acad Dermatol Venereol. 2009;23:239-40.
Kim MB, Kim GW, Park HJ, Kim HS, Chin HW, Kim SH, et al. Pimecrolimus 1% cream for the treatment of rosacea. J Dermatol. 2011;38:1135-9.
Koca R, Altinyazar HC, Ankarali H, Muhtar S, Tekin NS, Cinar S. A comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea: a randomized open-label clinical trial. Clin Exp Dermatol. 2010;35:251-6.
Breneman D, Savin R, VandePol C, Vamvakias G, Levy S, Leyden J. Double-blind, randomized, vehicle controlled clinical trial of once-daily benzoyl peroxide/clindamycin topical gel in the treatment of patients with moderate to severe rosacea. Int J Dermatol. 2004;43:381-7.
Sauder DN, Miller R, Gratton D, Danby W, Griffiths C, Phillips SB. The treatment of rosacea: the safety and efficacy of sodium sulfacetamide 10% and sulfur 5% lotion (Novacet) is demonstrated in a double-blind study. J Dermatolog Treat. 1997;8:79-85.
Koçak M, Yaĝli S, Vahapoĝlu G, Ekşioĝlu M. Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. A randomized double-blind placebo-controlled study. Dermatology. 2002;205:265-70.
Forstinger C, Kittler H, Binder M. Treatment of rosacea-like demodicidosis with oral ivermectin and topical permethrin cream. J Am Acad Dermatol. 1999;41:775-7.
Serdar ZA, Yasar S. Efficacy of 1% terbinafine cream in comparison with 0.75% metronidazole gel for the treatment of papulopustular rosacea. Cutan Ocul Toxicol. 2011;30:124-8.
Kligman AM. Topical tretinoin for rosacea: a preliminary report. J Dermatol Treat. 1993;4:71-73.
Ertl GA, Levine N, Kligman AM. A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. Arch Dermatol. 1994;130:319-24.
Shanler SD, Ondo AL. Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline. Arch Dermatol. 2007;143:1369-71.
Fowler J, Jarratt M, Moore A, , Meadows K, Pollack A, Steinhoff M, et al. Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol. 2012;166:633-41.
Sneddon IB. A clinical trial of tetracycline in rosacea. Br J Dermatol. 1966;78:649-652.
Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54:258-65.
Maibach H. Second generation tetracyclines, a dermatological overview: clinical uses and pharmacology. Cutis. 1991;48:411-7.
Theobald K, Bradshaw M, Leyden J. Anti-inflammatory doxycycline (40 mg contolled-release) confers maximum anti-inflammatory efficacy in rosacea. Skinmed. 2007;6:221-6.
McKeage K, Deeks ED. Doxycycline 40 mg capsules (30 mg immediaterelease/10 mg delayed-release beads): anti-inflammatory dose in rosacea. Am J Clin Dermatol. 2010;11:217-22.
Walker C, Puumala S, Golub LM, Stoner JA, Lee HM, Payne JB. Subantimicrobial dose doxycycline effects on osteopenic bone loss: microbial results. J Periodontol. 2007;78:1590-1601.
Del Rosso JQ, Webster GF, Kackson M, Rendon M, Rich P, Torok H, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56:791-802.
Fowler JF Jr. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J Drugs Dermatol. 2007;6:641-5.
Bakar O, Demircay Z, Gurbuz O. Therapeutic potential of azithromycin in rosacea. Int J Dermatol. 2004;43:151.
Torresani C. Clarithromycin: a new perspective in rosacea treatment. Int J Dermatol. 1998;37:343-9.
Torresani C, Pavesi A, Manata GC. Clarithromycin versus doxycycline in the treatment of rosacea. Int J Dermatol. 1997;36:938-46.
Erdogan FG, Yurtsever P, Aksoy D, Eskioglu F. Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea. Arch Dermatol. 1998;134:884-5.
Hoting E, Paul E, Plewig G. Treatment of rosacea with Isotretinoin. Int J Dermatol. 1986;25:660-3.
Pye RJ, Burton JL. Treatment of rosacea by metronidazole. Lancet. 1976;1:1211-2.
Saihan EM, Burton JL. A double-blind trial of metronidazole versus oxytetracycline therapy for rosacea. Br J Dermatol. 1980;102:443-5.
Sharique KE, Najm RA, Al-Salman HN. Oral zinc sulphate in the treatment of rosaca: a double-blind, placebo-controlled study. Int J Dermatol. 2006;45:857-61.
Butterwick KJ, Butterwick LS, Han A. Laser and light therapies for acne rosacea. J Drugs Dermatol. 2006;5:35-9.
Taub AF. Treatment of rosacea with intense pulsed light. J Drugs Dermatol. 2003;2:254-9.
Kassir R, Kolluru A, Kassir M.Intense pulsed light for the treatment of rosacea and telangiectasias. J Cosmet Laser Ther. 2011;13:216-22.
Papageorgiou P, Clayton W, Norwood S, Chopra S, Rustin M. Treatment of rosacea with intense pulsed light: significant improvement and long-lasting results. Br J Dermatol. 2008;159:628-32.
Schroeter CA, Haaf-von Below S, Neumann HA. Effective treatment of rosacea using Intense pulsed light systems. Derm Surg .2005;31:1285-9.
Neuhaus IM, Zane LT, Tope WD. Comparative efficacy of nonpurpuragenic pulsed dye laser and intense pulsed light for erythematotelangiectatic rosacea. Dermatol Surg. 2009;35:920-8.